Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECHARGE-1: Remibrutinib (LOU064) in Moderate to Severe Hidradenitis Suppurativa
CTR20251883Phase 3Active
- Sponsor
- 不适用/ 诺华（中国）生物医学研究有限公司
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of remibrutinib in hidradenitis suppurativa (HS) (3 arms), sponsored by 不适用/ 诺华（中国）生物医学研究有限公司. Primary endpoint: HiSCR50 at Week 16. Started Jul 2025; status: active.
02
Drugs
remibrutinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on CTR20251883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251883.